Equities

Universe Pharmaceuticals Inc

UPC:NAQ

Universe Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.378
  • Today's Change0.022 / 6.18%
  • Shares traded1.38m
  • 1 Year change-72.21%
  • Beta1.8043
Data delayed at least 15 minutes, as of Sep 19 2024 17:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Sep 30 2023202320222021
ASSETS
Cash And Short Term Investments191922
Total Receivables, Net111516
Total Inventory3.342.212.46
Prepaid expenses4.235.2610
Other current assets, total0.0600.24
Total current assets374250
Property, plant & equipment, net131415
Goodwill, net------
Intangibles, net0.150.160.18
Long term investments0.690.700.74
Note receivable - long term------
Other long term assets2.192.252.48
Total assets536070
LIABILITIES
Accounts payable4.593.085.31
Accrued expenses2.712.540.44
Notes payable/short-term debt5.483.944.33
Current portion long-term debt/capital leases------
Other current liabilities, total0.973.551.12
Total current liabilities141311
Total long term debt000
Total debt5.483.944.33
Deferred income tax------
Minority interest------
Other liabilities, total------
Total liabilities141311
SHAREHOLDERS EQUITY
Common stock0.070.070.07
Additional paid-in capital292929
Retained earnings (accumulated deficit)131927
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(2.41)(1.67)2.09
Total equity404659
Total liabilities & shareholders' equity536070
Total common shares outstanding3.633.633.63
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.